Department of General Surgery, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Department of Urology Surgery, Aerospace Center Hospital, Beijing, China.
Int J Med Sci. 2020 Feb 4;17(4):422-427. doi: 10.7150/ijms.39012. eCollection 2020.
: Pancreatic ductal adenocarcinoma (PDAC) with difficulty in early diagnosis does not respond well to conventional treatments and has not occurred significant improvement in the overall 5-year survival rates. Mesothelin (MSLN) is a tumor differentiation antigen expressed in several solid neoplasms and a limited number of healthy tissues. Its selective expression on malignant cells makes it an interesting candidate for investigation as a diagnostic and prognostic biomarker and as a therapeutic target. In this study, we detected the expression of MSLN in PDAC and analyzed the correlation between the expression of MSLN and clinicopathological data, so as to provide more theoretical basis for the role of MSLN in the diagnosis and treatment of PDAC. : Cancer and para-cancer tissues of 24 cases with PDAC were assessed by standardized immunohistochemical (IHC) detection with two kinds of anti-MSLN antibodies (EPR4509 and EPR19025-42) to detect their positive expression rates and study the correlation between the expression of MSLN and the clinicopathological data. : The two anti-MSLN antibodies of cancer tissues showed positive expression with tan yellow or tan brown granules diffusely distributed on the cell membrane in 22 of 24 cases with PDAC (positive rate of 91.67%), and the positive expression of the two antibodies EPR4509 and EPR19025-42 was completely consistent in all tissue samples. No expression of the two anti-MSLN antibodies was found in para-cancer tissues and the difference was statistically significant (χ=40.615, p=0.000, p<0.05) when compared with PDAC tissues. There was no significant correlation between MSLN expression and clinicopathological data, such as gender, tumor size, location, pathological stage, differentiation degree and lymph node metastasis (p>0.05). : MSLN was highly expressed in PDAC tissues, but not in paracancerous tissues. There was no significant correlation between MSLN expression and clinicopathological factors. The overexpression of MSLN may have promising prospects in diagnosis, targeted therapy and immunotherapy of PDAC.
胰腺导管腺癌（PDAC）早期诊断困难，对常规治疗反应不佳，整体 5 年生存率无显著提高。间皮素（MSLN）是一种在几种实体瘤和少数健康组织中表达的肿瘤分化抗原。其在恶性细胞上的选择性表达使其成为作为诊断和预后生物标志物以及治疗靶点的一个有趣候选物。在这项研究中，我们检测了 MSLN 在 PDAC 中的表达，并分析了 MSLN 表达与临床病理数据之间的相关性，为 MSLN 在 PDAC 的诊断和治疗中的作用提供了更多的理论依据。
采用两种抗 MSLN 抗体（EPR4509 和 EPR19025-42）通过标准化免疫组织化学（IHC）检测评估了 24 例 PDAC 的癌和癌旁组织，以检测其阳性表达率，并研究 MSLN 表达与临床病理数据之间的相关性。
在 24 例 PDAC 组织中，两种抗 MSLN 抗体的癌症组织均呈阳性表达，22 例（阳性率 91.67%）的细胞膜上弥漫分布着棕黄色或棕褐色颗粒，两种抗体 EPR4509 和 EPR19025-42 在所有组织样本中的阳性表达完全一致。癌旁组织中未检测到两种抗 MSLN 抗体的表达，与 PDAC 组织相比差异有统计学意义（χ=40.615，p=0.000，p<0.05）。MSLN 表达与性别、肿瘤大小、位置、病理分期、分化程度和淋巴结转移等临床病理资料无显著相关性（p>0.05）。
MSLN 在 PDAC 组织中高表达，但在癌旁组织中不表达。MSLN 表达与临床病理因素无显著相关性。MSLN 的过表达可能在 PDAC 的诊断、靶向治疗和免疫治疗方面具有广阔的前景。
